ADC Therapeutics Provides Business Updates
January 04, 2024 07:00 ET
|
ADC Therapeutics SA
ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing...
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
December 14, 2023 05:43 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
Folate Receptor Alpha Targeted Therapies - Exciting Advancements in Oncological R&D Revealed in Comprehensive Pipeline Review
December 14, 2023 05:28 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This pipeline review...
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023 05:15 ET
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
November 22, 2023 08:38 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
November 17, 2023 08:13 ET
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies
November 09, 2023 05:58 ET
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19...
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that...
ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am...
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...